Celldex Therapeutics (NASDAQ:CLDX) Now Covered by Analysts at Canaccord Genuity Group
Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research note released on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $64.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also recently weighed in on CLDX. UBS Group […]
Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research note released on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $64.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also recently weighed in on CLDX. UBS Group […]
